Jyong Biotech (MENS) vs Minerva Neurosciences (NERV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Minerva Neurosciences (NERV) has outperformed Jyong Biotech (MENS) over the past year, gaining 13.8% versus a loss of 95.9%. Jyong Biotech is the larger company by market cap ($158.1 million vs $152.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MENS | NERV |
|---|---|---|
| Share price | $2.08 | $3.19 |
| Market cap | $158.14M | $152.31M |
| 1-day change | -0.95% | -0.93% |
| YTD return | -46.84% | -19.90% |
| 1-year return | -95.89% | +13.78% |
| 5-year return | — | -70.19% |
| EPS (TTM) | $-0.06 | $-36.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $63.00 | $12.46 |
| 52-week low | $1.43 | $2.24 |
| Distance from 52-week high | -96.70% | -74.40% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +223.82% |
| Average volume | 45.62K | 183.63K |
| Shares outstanding | 74.23M | 47.75M |
| Employees | 27 | 7 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NERV has outperformed MENS by 109.7 percentage points over the past year.
About Jyong Biotech
MENS stock →Jyong Biotech Ltd., a science-driven biotechnology company, engages in the development and commercialization of plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops Botreso, for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 27 employees
About Minerva Neurosciences
NERV stock →Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
MENS vs NERV FAQ
Which is bigger, Jyong Biotech or Minerva Neurosciences?
Jyong Biotech (MENS) is larger, with a market capitalization of $158.14M compared with $152.31M for Minerva Neurosciences (NERV).
Which stock has performed better over the past year, MENS or NERV?
NERV returned +13.78% over the past 12 months, compared with -95.89% for MENS (price return, excluding dividends). Past performance does not predict future results.
Are Jyong Biotech and Minerva Neurosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.